TALWIN COMPOUND
LOE ApproachingNDAORALTABLET
Approved
Nov 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALWIN COMPOUND is an oral small-molecule tablet approved in 1975 for pain management. The product's specific mechanism of action and therapeutic indications are not currently documented in available data. As a legacy oral pain therapeutic, it likely addresses moderate pain conditions in adult patient populations.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a defensive, cost-focused team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's LOE-approaching status and mature lifecycle stage. Career opportunities are likely limited to defensive commercialization, pricing strategy, and market access roles rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on TALWIN COMPOUND at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.